PC
COGT icon

Polar Capital’s Cogent Biosciences COGT Stock Holding History

Polar Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$5.85M Buy
+625,000
New +$6.52M 0.04% 205

Other funds holding COGT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital's COGT Position: Q3 2020 in Review

Polar Capital opened a new position in Cogent Biosciences (COGT) in Q3 2020: 625,000 shares worth $5.85M. The stake represents 0.04% of the portfolio and ranks #205 among its holdings.

35 funds tracked by Wall St. Rank hold COGT as of Q3 2020.

  • Polar Capital held 625,000 shares of Cogent Biosciences worth $5.85M as of Q3 2020.
  • Cogent Biosciences was a new Polar Capital position in Q3 2020.
  • Cogent Biosciences made up 0.04% of Polar Capital's portfolio in Q3 2020, its #205 holding.
  • 35 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.